Physiomics PLC
LSE:PYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Physiomics PLC
Total Equity
Physiomics PLC
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Physiomics PLC
LSE:PYC
|
Total Equity
£393k
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-1%
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Total Equity
£463.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Total Equity
£39.9m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Total Equity
-£415k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Total Equity
£726k
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Total Equity
£43.6m
|
CAGR 3-Years
28%
|
CAGR 5-Years
10%
|
CAGR 10-Years
31%
|
|
Physiomics PLC
Glance View
Physiomics Plc engages in the provision of outsourced systems and computational biology services to pharmaceutical companies. The company is headquartered in Oxford, Oxfordshire and currently employs 7 full-time employees. The company went IPO on 2004-12-20. The firm offer Virtual Tumour technology and other tools to predict the effects of cancer treatments. The Company’s Virtual Tumour software platform is used to simulate the effects of anti-cancer agents on pre-clinical and human tumors. The company is used by companies ranging from startup biotech to global large-cap pharmaceuticals. The firm provides a range of Pharmacokinetic/Pharmacodynamics (PK/PD) services, usually in support of smaller companies where this function is outsourced. The Company’s services include oncology specialists, mechanistic modelling, PK/PD, quantitative systems pharmacology and mathematical modelling.
See Also
What is Physiomics PLC's Total Equity?
Total Equity
393k
GBP
Based on the financial report for Dec 31, 2025, Physiomics PLC's Total Equity amounts to 393k GBP.
What is Physiomics PLC's Total Equity growth rate?
Total Equity CAGR 10Y
-1%
Over the last year, the Total Equity growth was -6%. The average annual Total Equity growth rates for Physiomics PLC have been -20% over the past three years , -21% over the past five years , and -1% over the past ten years .
